Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells

Chiara Napoletano, Aurelia Rughetti, Mads P. Agervig Tarp, Julia Coleman, Eric P. Bennett, Gianfranco Picco, Patrizio Sale, Kaori Denda-Nagai, Tatsuro Irimura, Ulla Mandel, Henrik Clausen, Luigi Frati, Joyce Taylor-Papadimitriou, Joy Burchell, Marianna Nuti

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The type of interaction between tumor-associated antigens and specialized antigen-presenting cells such as dendritic cells (DCs) is critical for the type of immunity that will be generated. MUC1, a highly O-glycosylated mucin, is overexpressed and aberrantly glycosylated in several tumor histotypes. This results in the expression of tumor-associated glycoforms and in MUC1 carrying the tumor-specific glycan Tn (GalNAcα1-O-Ser/Thr). Glycopeptides corresponding to three tandem repeats of MUC1, enzymatically glycosylated with 9 or 15 mol of GalNAc, were shown to specifically bind and to be internalized by immature monocyte-derived DCs (iDCs). Binding required calcium and the GalNAc residue and was competed out by GalNAc polymer and Tn-MUC1 or Tn-MUC2 glycopeptides. The macrophage galactose-type C-type lectin (MGL) receptor expressed on iDCs was shown to be responsible for the binding. Confocal analysis and ELISA done on subcellular fractions of iDCs showed that the Tn-MUC1 glycopeptides colocalized with HLA class I and II compartments after internalization. Importantly, although Tn-MUC1 recombinant protein was bound and internalized by MGL, the glycoprotein entered the HLA class II compartment, but not the HLA class I pathway. These data indicate that MGL expressed on iDCs is an optimal receptor for the internalization of short GalNAcs carrying immunogens to be delivered into HLA class I and II compartments. Such glycopeptides therefore represent a new way of targeting the HLA class I and II pathways of DCs. These results have possible implications in designing cancer vaccines.

Original languageEnglish
Pages (from-to)8358-8367
Number of pages10
JournalCancer Research
Volume67
Issue number17
DOIs
Publication statusPublished - Sep 1 2007

Fingerprint

C-Type Lectins
Glycopeptides
Galactose
Dendritic Cells
Macrophages
Neoplasms
Cancer Vaccines
Tandem Repeat Sequences
Subcellular Fractions
Neoplasm Antigens
Mucins
Antigen-Presenting Cells
Recombinant Proteins
Polysaccharides
Monocytes
Immunity
Glycoproteins
Polymers
Enzyme-Linked Immunosorbent Assay
Calcium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. / Napoletano, Chiara; Rughetti, Aurelia; Agervig Tarp, Mads P.; Coleman, Julia; Bennett, Eric P.; Picco, Gianfranco; Sale, Patrizio; Denda-Nagai, Kaori; Irimura, Tatsuro; Mandel, Ulla; Clausen, Henrik; Frati, Luigi; Taylor-Papadimitriou, Joyce; Burchell, Joy; Nuti, Marianna.

In: Cancer Research, Vol. 67, No. 17, 01.09.2007, p. 8358-8367.

Research output: Contribution to journalArticle

Napoletano, C, Rughetti, A, Agervig Tarp, MP, Coleman, J, Bennett, EP, Picco, G, Sale, P, Denda-Nagai, K, Irimura, T, Mandel, U, Clausen, H, Frati, L, Taylor-Papadimitriou, J, Burchell, J & Nuti, M 2007, 'Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells', Cancer Research, vol. 67, no. 17, pp. 8358-8367. https://doi.org/10.1158/0008-5472.CAN-07-1035
Napoletano, Chiara ; Rughetti, Aurelia ; Agervig Tarp, Mads P. ; Coleman, Julia ; Bennett, Eric P. ; Picco, Gianfranco ; Sale, Patrizio ; Denda-Nagai, Kaori ; Irimura, Tatsuro ; Mandel, Ulla ; Clausen, Henrik ; Frati, Luigi ; Taylor-Papadimitriou, Joyce ; Burchell, Joy ; Nuti, Marianna. / Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. In: Cancer Research. 2007 ; Vol. 67, No. 17. pp. 8358-8367.
@article{975671420b29431a9f0a24ef8a68f394,
title = "Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells",
abstract = "The type of interaction between tumor-associated antigens and specialized antigen-presenting cells such as dendritic cells (DCs) is critical for the type of immunity that will be generated. MUC1, a highly O-glycosylated mucin, is overexpressed and aberrantly glycosylated in several tumor histotypes. This results in the expression of tumor-associated glycoforms and in MUC1 carrying the tumor-specific glycan Tn (GalNAcα1-O-Ser/Thr). Glycopeptides corresponding to three tandem repeats of MUC1, enzymatically glycosylated with 9 or 15 mol of GalNAc, were shown to specifically bind and to be internalized by immature monocyte-derived DCs (iDCs). Binding required calcium and the GalNAc residue and was competed out by GalNAc polymer and Tn-MUC1 or Tn-MUC2 glycopeptides. The macrophage galactose-type C-type lectin (MGL) receptor expressed on iDCs was shown to be responsible for the binding. Confocal analysis and ELISA done on subcellular fractions of iDCs showed that the Tn-MUC1 glycopeptides colocalized with HLA class I and II compartments after internalization. Importantly, although Tn-MUC1 recombinant protein was bound and internalized by MGL, the glycoprotein entered the HLA class II compartment, but not the HLA class I pathway. These data indicate that MGL expressed on iDCs is an optimal receptor for the internalization of short GalNAcs carrying immunogens to be delivered into HLA class I and II compartments. Such glycopeptides therefore represent a new way of targeting the HLA class I and II pathways of DCs. These results have possible implications in designing cancer vaccines.",
author = "Chiara Napoletano and Aurelia Rughetti and {Agervig Tarp}, {Mads P.} and Julia Coleman and Bennett, {Eric P.} and Gianfranco Picco and Patrizio Sale and Kaori Denda-Nagai and Tatsuro Irimura and Ulla Mandel and Henrik Clausen and Luigi Frati and Joyce Taylor-Papadimitriou and Joy Burchell and Marianna Nuti",
year = "2007",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-07-1035",
language = "English",
volume = "67",
pages = "8358--8367",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells

AU - Napoletano, Chiara

AU - Rughetti, Aurelia

AU - Agervig Tarp, Mads P.

AU - Coleman, Julia

AU - Bennett, Eric P.

AU - Picco, Gianfranco

AU - Sale, Patrizio

AU - Denda-Nagai, Kaori

AU - Irimura, Tatsuro

AU - Mandel, Ulla

AU - Clausen, Henrik

AU - Frati, Luigi

AU - Taylor-Papadimitriou, Joyce

AU - Burchell, Joy

AU - Nuti, Marianna

PY - 2007/9/1

Y1 - 2007/9/1

N2 - The type of interaction between tumor-associated antigens and specialized antigen-presenting cells such as dendritic cells (DCs) is critical for the type of immunity that will be generated. MUC1, a highly O-glycosylated mucin, is overexpressed and aberrantly glycosylated in several tumor histotypes. This results in the expression of tumor-associated glycoforms and in MUC1 carrying the tumor-specific glycan Tn (GalNAcα1-O-Ser/Thr). Glycopeptides corresponding to three tandem repeats of MUC1, enzymatically glycosylated with 9 or 15 mol of GalNAc, were shown to specifically bind and to be internalized by immature monocyte-derived DCs (iDCs). Binding required calcium and the GalNAc residue and was competed out by GalNAc polymer and Tn-MUC1 or Tn-MUC2 glycopeptides. The macrophage galactose-type C-type lectin (MGL) receptor expressed on iDCs was shown to be responsible for the binding. Confocal analysis and ELISA done on subcellular fractions of iDCs showed that the Tn-MUC1 glycopeptides colocalized with HLA class I and II compartments after internalization. Importantly, although Tn-MUC1 recombinant protein was bound and internalized by MGL, the glycoprotein entered the HLA class II compartment, but not the HLA class I pathway. These data indicate that MGL expressed on iDCs is an optimal receptor for the internalization of short GalNAcs carrying immunogens to be delivered into HLA class I and II compartments. Such glycopeptides therefore represent a new way of targeting the HLA class I and II pathways of DCs. These results have possible implications in designing cancer vaccines.

AB - The type of interaction between tumor-associated antigens and specialized antigen-presenting cells such as dendritic cells (DCs) is critical for the type of immunity that will be generated. MUC1, a highly O-glycosylated mucin, is overexpressed and aberrantly glycosylated in several tumor histotypes. This results in the expression of tumor-associated glycoforms and in MUC1 carrying the tumor-specific glycan Tn (GalNAcα1-O-Ser/Thr). Glycopeptides corresponding to three tandem repeats of MUC1, enzymatically glycosylated with 9 or 15 mol of GalNAc, were shown to specifically bind and to be internalized by immature monocyte-derived DCs (iDCs). Binding required calcium and the GalNAc residue and was competed out by GalNAc polymer and Tn-MUC1 or Tn-MUC2 glycopeptides. The macrophage galactose-type C-type lectin (MGL) receptor expressed on iDCs was shown to be responsible for the binding. Confocal analysis and ELISA done on subcellular fractions of iDCs showed that the Tn-MUC1 glycopeptides colocalized with HLA class I and II compartments after internalization. Importantly, although Tn-MUC1 recombinant protein was bound and internalized by MGL, the glycoprotein entered the HLA class II compartment, but not the HLA class I pathway. These data indicate that MGL expressed on iDCs is an optimal receptor for the internalization of short GalNAcs carrying immunogens to be delivered into HLA class I and II compartments. Such glycopeptides therefore represent a new way of targeting the HLA class I and II pathways of DCs. These results have possible implications in designing cancer vaccines.

UR - http://www.scopus.com/inward/record.url?scp=34548593215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548593215&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-1035

DO - 10.1158/0008-5472.CAN-07-1035

M3 - Article

C2 - 17804752

AN - SCOPUS:34548593215

VL - 67

SP - 8358

EP - 8367

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 17

ER -